The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Secondini, Chiara ^a   Wetterwald, Antoinette ^a   Schwaninger, Ruth ^a   Thalmann, George N ^a   Cecchini, Marco G ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NOGGIN; BONE MORPHOGENETIC PROTEIN; CARRIER PROTEIN; NOGGIN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; CARCINOGENESIS; CELL ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOLYTIC BONE METASTASIS; PROSTATE CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; BONE TUMOR; DRUG ANTAGONISM; MALE; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CARRIER PROTEINS; CELL LINE, TUMOR; HUMANS; MALE; OSTEOBLASTS; OSTEOLYSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79251571488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016078     Document Type: Article

References (66)

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583.
2. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34: 646-653.
3. Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10: 169-180.
4. Lage MJ, Barber BL, Harrison DJ, Jun S (2008) The cost of treating skeletalrelated events in patients with prostate cancer. Am J Manag Care 14: 317-322.
5. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
6. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80: 1546-1556.
7. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.
8. Suva LJ, Griffin RJ, Makhoul I (2009) Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 16: 703-713.
9. Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10: 159-178.
10. Mundy GR, Sterling JA (2008) Metastastic solid tumors to bone. In: Rosen CJ, ed. Primer on the netabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington DC: American Society for Bone and Mineral Research. Pp 374-378.
11. GD (2010) Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab.
12. Bataille R, Chappard D, Alexandre C, Dessauw P, Sany J (1986) Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 53: 805-810.
13. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, et al. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49: 192-198.
14. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD, Jr. (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42: 669-680.
15. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myelomaderived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207.
16. Heath DJ, Chantry AD, Buckle C, Coulton L, Shaughnessy JD, et al. (2008) Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. Calcified Tissue International 83: 6-6.
17. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, et al. (2007) Lack of noggin expression by cancer cells is adeterminant of the osteoblast response in bone metastases. Am J Pathol 170: 160-175.
18. Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, et al. (2002) Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 160: 1143-1153.
19. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, 3rd, et al. (2006) Tcell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13: 1480-1492.
20. Gazzerro E, Du Z, Devlin RD, Rydziel S, Priest L, et al. (2003) Noggin arrests stromal cell differentiation in vitro. Bone 32: 111-119.
21. Sundquist KT, Cecchini MG, Marks SC, Jr. (1995) Colony-stimulating factor-1 injections improve but do not cure skeletal sclerosis in osteopetrotic (op) mice. Bone 16: 39.
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987) Bone Histomorphometry - Standardization of Nomenclature, Symbols, and Units. Journal of Bone and Mineral Research 2: 595-610.
23. Gazzerro E, Gangji V, Canalis E (1998) Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102: 2106-2114.
24. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH (2004) Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64: 8276-8284.
25. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Journal of Clinical Investigation 98: 1544-1549.
26. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigation 103: 197-206.
27. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, et al. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America 98: 11581-11586.
28. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, et al. (2003) Interleukin- 8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37.
29. Canalis E (2009) Growth factor control of bone mass. J Cell Biochem 108: 769-777.
30. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
31. Clines GA, Mohammad KS, Bao YD, Stephens OW, Suva LJ, et al. (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology 21: 486-498.
32. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, et al. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165.
33. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA (1994) Histomorphometric Evidence for Osteoclast-Mediated Bone-Resorption in Metastatic Breast-Cancer. Bone 15: 161-166.
34. Vukmirovic-Popovic S, Colterjohn N, Lhotak S, Duivenvoorden WCM, Orr FW, et al. (2002) Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone 31: 529-535.
35. Kulenkampff HA, Dreyer T, Kersjes W, Delling G (1986) Histomorphometric Analysis of Osteoclastic Bone-Resorption in Metastatic Bone-Disease from Various Primary Malignomas. Virchows Archiv a-Pathological Anatomy and Histopathology 409: 817-828.
36. Parfitt A (1995) Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. The Canadian journal of oncology 5: 1-10.
37. Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, et al. (2004) Breast cancer cells induce osteoblast apoptosis: A possible contributor to bone degradation. Journal of Cellular Biochemistry 91: 265-276.
38. Mercer RR, Miyasaka C, Mastro AM (2004) Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clinical & Experimental Metastasis 21: 427-435.
39. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, et al. (2010) The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 70: 412-424.
40. Brunet LJ, McMahon JA, McMahon AP, Harland RM (1998) Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457.
41. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, et al. (2003) Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144: 1972-1978.
42. Wu XB, Li Y, Schneider A, Yu W, Rajendren G, et al. (2003) Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 112: 924-934.
43. Barnes J, Anthony CT, Wall N, Steiner MS (1995) Bone morphogenetic protein- 6 expression in normal and malignant prostate. World J Urol 13: 337-343.
44. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, et al. (1997) Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57: 4427-4431.
45. Dai J, Keller J, Zhang J, Lu Y, Yao Z, et al. (2005) Bone morphogenetic protein- 6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65: 8274-8285.
46. Hall CL, Kang S, MacDougald OA, Keller ET (2006) Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97: 661-672.
47. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, et al. (1994) Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24: 204-211.
48. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, et al. (2007) TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24: 609-617.
49. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, et al. (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047-1057.
50. Neri B, Cecchettin M, Pacini P, Bartalucci S, Gemelli MT, et al. (1989) Osteocalcin as a biological marker in the therapeutic management of breast cancer bone metastases. Cancer Invest 7: 551-555.
51. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111.
52. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Jr., et al. (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24: 425-436.
53. Bu G, Lu W, Liu CC, Selander K, Yoneda T, et al. (2008) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 123: 1034-1042.
54. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65: 7554-7560.
55. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97: 964-970.
56. Hartmann C (2006) A Wnt canon orchestrating osteoblastogenesis. Trends in Cell Biology 16: 151-158.
57. Dai JL, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, et al. (2008) Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Research 68: 5785-5794.
58. Ohazama A, Johnson EB, Ota MS, Choi HY, Porntaveetus T, et al. (2008) Lrp4 modulates extracellular integration of cell signaling pathways in development. PLoS One 3: e4092.
59. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N (2009) Characterization of Wise Protein and Its Molecular Mechanism to Interact with both Wnt and BMP Signals. Journal of Biological Chemistry 284: 23159-23168.
60. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, et al. (2009) Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis. Clinical Cancer Research 15: 7175-7185.
61. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CWGM, et al. (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Research 65: 7682-7690.
62. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551-3557.
63. Yaccoby S, Wezernan MJ, Zangari M, Walker R, Cottler-Fox M, et al. (2006) Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica-the Hematology Journal 91: 192-199.
64. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, et al. (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38: 154-166.
65. Dougall WC, Chaisson M (2006) The RANK/RANKL/OPG triad in cancerinduced bone diseases. Cancer and Metastasis Reviews 25: 541-549.
66. Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA (2010) Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma. Curr Pharm Des.